替拉珠单抗与生活质量：深入探讨银屑病及其治疗对不同领域的影响——心理社会生活障碍是否应被视为一种合并症？
Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?
作者信息
Licata Gaetano, Di Brizzi Eugenia Veronica, Castelli Franco, Giuffrida Giorgia, Stroppiana Elena, Dattola Annunziata, Richetta Antonio Giovanni, De Col Elena, Peila Rossana, Siliquini Niccolò, Solaroli Carmen, Zanetta Roberta, Cerulli Emilia, Galdo Giovanna, Giordano Domenico, Faure Elisa, Papaianni Valeria, Pertusi Ginevra, Uzzauto Maria Teresa, Loconsole Francesco, Zichichi Leonardo
机构信息
Dermatology Unit, San Antonio Abate Hospital, 91016 Trapani, Italy.
Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
出版信息
J Clin Med. 2025 Jan 2;14(1):223. doi: 10.3390/jcm14010223.
: Psoriasis is a chronic inflammatory skin disease that may have a significant impact on patients' quality of life. Alongside clinical scores, treatment goals include improvements in patients' quality of life, divided into its social, working and psychosocial life aspects. Indeed, psychological impairment should always be considered in the management of moderate-to-severe psoriasis. Tildrakizumab, an anti-IL-23, is approved for the management of moderate-to-severe psoriasis. Both clinical trials and real-life studies show its efficacy and safety; however, no studies have evaluated how tildrakizumab may improve different domains of quality of life, including physical, psychological, and social aspects of patients' quality of life. The objective was to evaluate the effectiveness of tildrakizumab in the management of moderate-to-severe psoriasis, focusing on the impact on all domains of patients' quality of life. : A 28-week multicenter, real-life, retrospective study was performed enrolling patients affected by moderate-to-severe psoriasis undergoing treatment with tildrakizumab. PASI and DLQI were evaluated at each follow-up (W16, W28). A sub-analysis of each DLQI question evaluated different domains of quality of life, including physical, psychological, and social aspects of patients' quality-of-life. : A total of 62 patients were enrolled. At week 28, 97.1%, 85.7%, and 54.3% of patients achieved PASI75, PASI90, and PASI100, respectively. DLQI showed a significant reduction from baseline (20.3 ± 5.5) to week 28 (0.9 ± 2.2, < 0.0001), with up to 82.9% achieving DLQI < 1. Sub-analysis of each question (Q1-Q10) showed a reduction in the value of each answer from baseline to week 28. : The results confirm tildrakizumab as an effective and safe treatment in real life, positively affecting all domains of quality of life, with significant impact already appreciable at week 16 of follow-up.
银屑病是一种慢性炎症性皮肤病，可能对患者的生活质量产生重大影响。除临床评分外，治疗目标还包括改善患者的生活质量，这可分为社会、工作和心理社会生活等方面。事实上，在中重度银屑病的管理中，应始终考虑心理损害。抗白细胞介素-23药物替拉珠单抗已被批准用于中重度银屑病的治疗。临床试验和现实生活研究均显示了其疗效和安全性；然而，尚无研究评估替拉珠单抗如何改善生活质量的不同领域，包括患者生活质量的身体、心理和社会方面。目的是评估替拉珠单抗在中重度银屑病管理中的有效性，重点关注对患者生活质量所有领域的影响。：开展了一项为期28周的多中心、现实生活、回顾性研究，纳入接受替拉珠单抗治疗的中重度银屑病患者。在每次随访（第16周、第28周）时评估银屑病面积和严重程度指数（PASI）和皮肤病生活质量指数（DLQI）。对每个DLQI问题的亚分析评估了生活质量的不同领域，包括患者生活质量的身体、心理和社会方面。：共纳入62例患者。在第28周时，分别有97.1%、85.7%和54.3%的患者达到PASI75、PASI90和PASI100。DLQI显示从基线（20.3±5.5）到第28周显著降低（0.9±2.2，P<0.0001），高达82.9%的患者DLQI<1。对每个问题（问题1-问题10）的亚分析显示，从基线到第28周每个答案的值均降低。：结果证实替拉珠单抗在现实生活中是一种有效且安全的治疗方法，对生活质量的所有领域均有积极影响，在随访第16周时就已产生显著影响。
Zotero 插件